⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2024Open Access

Figure S4 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity

Ying Kong Xinyue Zhao Zhaofu Wang Siqi Yuan Sheng Chen Shidi Lou Shichao Ma Yunfeng Li Xinghao Wang Yangfeng Ge Guobin Li Hongbing Yang Mengxi Zhao Dandan Li Hailong Zhang Wenfu Tan Juan Wang

View Full Paper

Ask AI

Bookmark

Share

Abstract

Molecular dynamics (MD) simulations on the FGFR1/2/3: BR-cpd7: CRBN complexes. A, green-light-blue: CRBN-FGFR1; gray-light-pink: CRBN-FGFR3. B, blue-yellow: CRBN-FGFR2 unphosphorylated; purple-yellow: CRBN-FGFR2 phosphorylated.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kong et al. (2024) studied this question.

synapsesocial.com/papers/68e5e0e0b6db643587574cc0 https://doi.org/10.1158/1535-7163.26423452.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S5 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity2024
2Figure S2 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity2024
3Figure S3 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity2024
4Data from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity2024
5Table S1 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity2024

Table S1 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity2024
Figure S6 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity2024
A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity2024